Evolution in the management of non-small cell lung cancer in Brazil.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.Current oncology reports · 2023
   Review
2. Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives.TH open : companion journal to thrombosis and haemostasis · 2021
   Article
3. Cancer-associated thrombosis: the when, how and why.European respiratory review : an official journal of the European Respiratory Society · 2019
   Review
4. Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2019
   Article
5. Extended anticoagulation after venous thromboembolism: should it be done?Therapeutic advances in respiratory disease
   Review

Corrections and comments

• Comment on
  Survival in a cohort of patients with lung cancer: the role of age and gender in prognosis.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as